Aeglea BioTherapeutics Provides AEB1102 Program and Corporate Update
May 23, 2017 12:09 pm UTC| Business
--Announces three single agent expansion arms for AEB1102 solid tumor trials-- --Provides update on AEB1102 program in Arginase 1 Deficiency-- --Company names Aaron Schuchart as chief business officer-- AUSTIN, Texas,...
Aeglea BioTherapeutics Provides AEB1102 Program and Corporate Update
May 23, 2017 12:09 pm UTC| Business
--Announces three single agent expansion arms for AEB1102 solid tumor trials-- --Provides update on AEB1102 program in Arginase 1 Deficiency-- --Company names Aaron Schuchart as chief business officer-- AUSTIN, Texas,...
Aeglea BioTherapeutics Provides AEB1102 Program and Corporate Update
May 23, 2017 12:09 pm UTC| Business
--Announces three single agent expansion arms for AEB1102 solid tumor trials-- --Provides update on AEB1102 program in Arginase 1 Deficiency-- --Company names Aaron Schuchart as chief business officer-- AUSTIN, Texas,...
Aeglea BioTherapeutics Provides AEB1102 Program and Corporate Update
May 23, 2017 12:09 pm UTC| Business
--Announces three single agent expansion arms for AEB1102 solid tumor trials-- --Provides update on AEB1102 program in Arginase 1 Deficiency-- --Company names Aaron Schuchart as chief business officer-- AUSTIN, Texas,...
Aeglea BioTherapeutics Provides AEB1102 Program and Corporate Update
May 23, 2017 12:09 pm UTC| Business
--Announces three single agent expansion arms for AEB1102 solid tumor trials-- --Provides update on AEB1102 program in Arginase 1 Deficiency-- --Company names Aaron Schuchart as chief business officer-- AUSTIN, Texas,...
Aeglea BioTherapeutics Provides AEB1102 Program and Corporate Update
May 23, 2017 12:09 pm UTC| Business
--Announces three single agent expansion arms for AEB1102 solid tumor trials-- --Provides update on AEB1102 program in Arginase 1 Deficiency-- --Company names Aaron Schuchart as chief business officer-- AUSTIN, Texas,...
Aeglea BioTherapeutics Provides AEB1102 Program and Corporate Update
May 23, 2017 12:09 pm UTC| Business
--Announces three single agent expansion arms for AEB1102 solid tumor trials-- --Provides update on AEB1102 program in Arginase 1 Deficiency-- --Company names Aaron Schuchart as chief business officer-- AUSTIN, Texas,...